Raltegravir Potassium

Pronunciation

Class: Integrase Inhibitors
Chemical Name: N - [(4 - Fluorophenyl)methyl] - 1,6 - dihydro - 5 - hydroxy - 1 - methyl - 2 - {1 - methyl - 1 - [[(5 - methyl - 1,3,4 - oxadiazol - 2 - yl)carbonyl]amino]ethyl} - 6 - oxo - 4 - pyrimidinecarboxamide monopotassium salt
Molecular Formula: C20H20FKN6O5
CAS Number: 871038-72-1
Brands: Isentress

Introduction

Antiretroviral; HIV integrase strand transfer inhibitor (INSTI).1 200

Uses for Raltegravir Potassium

Treatment of HIV Infection

Treatment of HIV-1 infection in conjunction with other antiretrovirals.1 8 14

For initial treatment in antiretroviral-naive adults and adolescents, experts state that raltegravir in conjunction with tenofovir disoproxil fumarate (tenofovir DF) and emtricitabine (or lamivudine) is a recommended INSTI-based regimen that can be used regardless of baseline viral load or CD4+ T-cell count;200 raltegravir in conjunction with abacavir and lamivudine (or emtricitabine) is an alternative INSTI-based regimen for initial treatment, but use only in those who are human leukocyte antigen (HLA)-B*5701 negative.200

Slideshow: Flashback: FDA Drug Approvals 2013

For initial treatment in pediatric patients, experts state that INSTI-based regimen of raltegravir and 2 NRTIs can be considered in those ≥2 years of age in special circumstances when preferred or alternative antiretrovirals cannot be used.201

Safety and efficacy not established in pediatric patients <4 weeks of age.1

Postexposure Prophylaxis following Occupational Exposure to HIV

Postexposure prophylaxis of HIV infection following occupational exposure (PEP) in health-care personnel and others exposed via percutaneous injury (e.g., needlestick, cut with sharp object) or mucous membrane or nonintact skin (e.g., chapped, abraded, dermatitis) contact with blood, tissue, or other body fluids that might contain HIV.199

USPHS recommends 3-drug regimen of raltegravir and emtricitabine and tenofovir DF as preferred regimen for PEP following occupational exposures to HIV.199 Alternative dual NRTIs for use with raltegravir are tenofovir DF and lamivudine, zidovudine and lamivudine, or zidovudine and emtricitabine.199

Management of occupational exposures to HIV is complex and evolving; consult infectious disease specialist, clinician with expertise in administration of antiretroviral agents, and/or National Clinicians’ Postexposure Prophylaxis Hotline (PEPline at 888-448-4911) whenever possible.199 Do not delay initiation of PEP while waiting for expert consultation.199

Raltegravir Potassium Dosage and Administration

Administration

Oral Administration

Administer orally without regard to food.1

Chewable Tablets

May be chewed or swallowed whole.1 If needed, 100-mg chewable tablet can be divided into equal halves.1

Used in pediatric patients weighing ≥11 kg to <25 kg.1 Also may be used as alternative in pediatric patients weighing ≥25 kg who cannot swallow film-coated tablets.1

Film-coated Tablets

Must be swallowed whole.1

Used in adults, adolescents, and pediatric patients weighing ≥25 kg.1

Oral Suspension

Immediately prior to use, contents of a single-use packet of powder for oral suspension must be mixed in 5 mL of water to provide a suspension containing 20 mg/mL.1 Appropriate dosage of the suspension is then administered orally using dosing syringe provided by the manufacturer.1

To prepare oral suspension, use dosing syringe provided by the manufacturer to measure and add 5 mL of water to the mixing cup provided by the manufacturer.1 Open a single-dose packet of powder for oral suspension and pour entire contents into the mixing cup, tightly close mixing cup, and gently swirl for 30–60 seconds.1 Suspension will appear cloudy.1

Draw recommended dosage of oral suspension into the dosing syringe and administer orally.1

Administer within 30 minutes of mixing; discard any remaining suspension.1 After each use, handwash dosing syringe and mixing cup with warm water and dish soap, rinse with water, and air dry.1

Used in pediatric patients ≥4 weeks of age weighing ≥3 kg to <20 kg.1

Dosage

Available as raltegravir potassium; dosage expressed in terms of raltegravir.1

Must be given in conjunction with other antiretrovirals.1

Chewable tablets and oral suspension are not bioequivalent to film-coated tablets;1 do not substitute chewable tablets or oral suspension for the 400-mg film-coated tablet.1

Pediatric Patients

Treatment of HIV Infection
Oral

Infants and children ≥4 weeks of age weighing ≥3 kg to <20 kg (oral suspension): Dosage based on weight (approximately 6 mg/kg twice daily; up to 100 mg twice daily).1 (See Table 1.)

Pediatric patients weighing ≥11 kg to <25 kg (chewable tablets): Dosage based on weight (approximately 6 mg/kg twice daily; up to 300 mg twice daily).1 (See Table 1.)

Table 1. Dosage of Raltegravir (Oral Suspension or Chewable Tablets) in Pediatric Patients 4 Weeks of Age or Older Weighing at Least 3 kg to Less Than 25 kg

Body Weight (kg)

Dosage of Oral Suspension Containing 20 mg/mL

Dosage of Chewable Tablets

3 to <4

20 mg (1 mL) twice daily

Do not use

4 to <6

30 mg (1.5 mL) twice daily

Do not use

6 to <8

40 mg (2 mL) twice daily

Do not use

8 to <11

60 mg (3 mL) twice daily

Do not use

11 to <14

80 mg (4 mL) twice daily

75 mg twice daily (three 25-mg tablets twice daily)

14 to <20

100 mg (5 mL) twice daily

100 mg twice daily (one 100-mg tablet twice daily)

20 to <25

Do not use

150 mg twice daily (one and one-half 100-mg tablets twice daily)

Children and adolescents weighing ≥25 kg (film-coated tablets): 400 mg twice daily (one 400-mg film-coated tablet twice daily).1

Children and adolescents weighing ≥25 kg (chewable tablets): Dosage based on weight (approximately 6 mg/kg twice daily; up to 300 mg twice daily).1 (See Table 2.) Used as alternative in those who cannot swallow film-coated tablets.1

Table 2. Alternative Dosage of Raltegravir (Chewable Tablets) in Pediatric Patients Weighing ≥25 kg and Unable to Swallow Film-coated Tablets

Body Weight (kg)

Dosage

Number of Chewable Tablets

25 to <28

150 mg twice daily

One and one-half 100-mg tablets twice daily

28 to <40

200 mg twice daily

Two 100-mg tablets twice daily

≥40

300 mg twice daily

Three 100-mg tablets twice daily

Adults

Treatment of HIV Infection
Oral

Film-coated tablets: 400 mg twice daily (one 400-mg film-coated tablet twice daily).1

Postexposure Prophylaxis following Occupational Exposure to HIV
Oral

400 mg twice daily.199 Used in conjunction with 2 NRTIs (see Postexposure Prophylaxis following Occupational Exposure to HIV under Uses).199

Initiate PEP as soon as possible following exposure to HIV (preferably within hours); continue for 4 weeks, if tolerated.199

Prescribing Limits

Pediatric Patients

Treatment of HIV Infection
Pediatric Patients ≥4 Weeks of Age Weighing ≥3 kg to < 20 kg
Oral

Oral Suspension: Maximum 100 mg twice daily.1

Pediatric Patients Weighing ≥11 kg
Oral

Chewable tablets: Maximum 300 mg twice daily.1

Special Populations

Hepatic Impairment

Dosage adjustment not necessary in patients with mild to moderate hepatic impairment;1 200 data not available in patients with severe hepatic impairment.1 (See Hepatic Impairment under Cautions.)

Renal Impairment

Dosage adjustment not necessary.1 200 Avoid administering before dialysis session.1 (See Renal Impairment under Cautions.)

Geriatric Patients

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1

Cautions for Raltegravir Potassium

Contraindications

  • Manufacturer states none known.1

Warnings/Precautions

Sensitivity Reactions

Severe Skin and Hypersensitivity Reactions

Severe, potentially life-threatening skin reactions reported, including some fatalities.1 Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction (including hepatic failure) have occurred.1

Immediately discontinue raltegravir and any other suspect agents if signs or symptoms of severe skin or hypersensitivity reactions occur, including (but not limited to) severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, or angioedema.1 Monitor clinical status, including liver aminotransferases, and initiate appropriate therapy.1

Life-threatening reactions could occur if there is a delay in discontinuing raltegravir or other suspect agents after onset of severe rash.1

Phenylketonuria

Advise individuals with phenylketonuria (i.e., homozygous genetic deficiency of phenylalanine hydroxylase) and other individuals who must restrict phenylalanine intake that raltegravir chewable tablets contain aspartame (NutraSweet),1 which is metabolized in the GI tract to phenylalanine.104 105

Each 25- or 100-mg chewable tablet provides approximately 0.05 or 0.1 mg of phenylalanine, respectively.1

Interactions

Concomitant use with drugs that are potent inducers of UGT 1A1 (e.g., rifampin) may result in decreased plasma concentrations of raltegravir.1 (See Interactions.)

Musculoskeletal Effects

Increased serum CK concentrations, myopathy, and rhabdomyolysis reported.1

Use with caution in patients at increased risk of myopathy or rhabdomyolysis, including those receiving concomitant therapy with drugs known to cause myopathy or rhabdomyolysis (e.g., hydroxymethylglutaryl-CoA [HMG-CoA] reductase inhibitors [statins], fenofibrate, gemfibrozil, zidovudine) and those with history of rhabdomyolysis, myopathy, or increased serum CK concentrations.1

Individuals with HBV or HCV Infection

Safety profile in HIV-infected patients with HBV or HCV coinfection is similar to that in HIV-infected patients without such coinfection, but increased AST and ALT concentrations reported more frequently.1

Immune Reconstitution Syndrome

During initial treatment, patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium, M. tuberculosis, cytomegalovirus [CMV], Pneumocystis jiroveci [formerly P. carinii], varicella-zoster virus [VZV]); this may necessitate further evaluation and treatment.1

Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barré syndrome) reported to occur in the setting of immune reconstitution; time to onset is more variable and can occur many months after initiation of antiretroviral therapy.1

Specific Populations

Pregnancy

Category C.1

Antiretroviral Pregnancy Registry at 800-258-4263 or .1 202

Although data are limited regarding use in pregnant women, experts state that raltegravir and 2 NRTIs can be considered an alternative regimen for initial treatment in pregnant women, especially when drug interactions with PI-based regimens are a concern.202

Lactation

Distributed into milk in rats; not known whether distributed into human milk.1

Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant.1 202

Pediatric Use

Safety and efficacy not established in pediatric patients <4 weeks of age.1

Safety profile in infants, children, and adolescents 4 weeks to 18 years of age is similar to that in adults.1

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1

Use with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1

Hepatic Impairment

Risk for further elevations in hepatic enzyme concentrations in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.1 (See Hepatic Impairment under Dosage and Administration.)

Renal Impairment

Not known if removed by dialysis; avoid administering drug before dialysis session.1 (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Insomnia, headache, dizziness, nausea, fatigue, hyperglycemia, decreased neutrophil count, and increased serum aminotransferases, total bilirubin, lipase, pancreatic amylase, CK, cholesterol.1

Interactions for Raltegravir Potassium

Metabolized by UGT 1A1.1 Does not inhibit UGT 1A1 or UGT 2B7 in vitro.1

Not a substrate for CYP isoenzymes.1 Does not inhibit CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A and does not induce CYP1A2, 2B6, or 3A4.1

Does not inhibit P-glycoprotein-mediated transport.1

Drugs Affecting or Metabolized by UGT 1A1

Potential pharmacokinetic interactions with drugs that are potent inducers of UGT 1A1 (decreased plasma concentrations of raltegravir)1 200 or inhibitors of UGT 1A1 (increased plasma concentrations of raltegravir).1

Not expected to affect pharmacokinetics of drugs that are substrates for UGT 1A1 or UGT 2B7.1

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Pharmacokinetic interactions unlikely with drugs that are substrates for CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A.1

Drugs Affected by P-glycoprotein Transport

Pharmacokinetic interactions unlikely with drugs that are substrates for P-glycoprotein.1

Specific Drugs

Drug

Interaction

Comments

Abacavir

In vitro evidence of additive to synergistic antiretroviral effects1

Antacids, aluminum-, calcium-, or magnesium-containing

Decreased concentrations and AUC of raltegravir1

Aluminum- and/or magnesium-containing antacids: Do not use concomitantly or within 2 hours before or after raltegravir1 200

Calcium-containing antacids: Dosage adjustments not needed1 200

Anticonvulsants (phenobarbital, phenytoin)

Phenytoin and/or phenobarbital potentially may affect the UGT 1A1 pathway;11 effect on raltegravir pharmacokinetics unknown1

Concomitant use of phenytoin and/or phenobarbital was prohibited in expanded-access program due to potential effect on UGT 1A1 pathway11

Antimycobacterials, rifamycins (rifabutin, rifampin, rifapentine)

Rifabutin: Increased raltegravir concentrations and AUC200

Rifampin: Decreased raltegravir peak plasma concentrations and AUC1 11 200

Rifabutin: Dosage adjustments not needed200

Rifampin: In adults, increase dosage of raltegravir film-coated tablets to 800 mg twice daily1 200 and monitor closely for virologic response or consider use of rifabutin instead;200 data insufficient to make dosage recommendations for concomitant use in children and adolescents <18 years of age1

Rifapentine: Concomitant use not recommended200

Atazanavir

Atazanavir or ritonavir-boosted atazanavir: Increased raltegravir concentrations and AUC1 200

In vitro evidence of additive to synergistic antiretroviral effects1

Atazanavir or ritonavir-boosted atazanavir: Dosage adjustments not needed1 200

Benzodiazepines (e.g., midazolam)

Raltegravir not expected to affect pharmacokinetics of midazolam1 10

Boceprevir

No clinically important effects on boceprevir or raltegravir pharmacokinetics1 16 200

Dosage adjustments not needed1 16 200

Buprenorphine

No clinically important effect on buprenorphine pharmacokinetics200

Dosage adjustments not needed200

Darunavir

Ritonavir-boosted darunavir: Decreased raltegravir AUC;200 no clinically important effect on pharmacokinetics of ritonavir-boosted darunavir1

Ritonavir-boosted darunavir: Dosage adjustments not needed200

Delavirdine

In vitro evidence of additive to synergistic antiretroviral effects1

Didanosine

In vitro evidence of additive to synergistic antiretroviral effects1

Dolutegravir

No in vitro evidence of antagonistic antiretroviral effects236

Efavirenz

Decreased raltegravir concentrations and AUC;1 11 200 clinical importance unknown11

In vitro evidence of additive to synergistic antiretroviral effects1

Some experts state dosage adjustments not needed200

Elvitegravir and cobicistat

Fixed combination of elvitegravir, cobicistat, emtricitabine, and tenofovir (EVG/COBI/TDF/FTC): Data not available200

EVG/COBI/TDF/FTC: Concomitant use not recommended200

Enfuvirtide

In vitro evidence of additive to synergistic antiretroviral effects1

Etravirine

Decreased raltegravir concentrations and AUC; no clinically important effect on etravirine pharmacokinetics;1 200 214 clinical importance unknown1

No in vitro evidence of antagonistic antiretroviral effects214

Dosage adjustments not needed200 214

Estrogens/progestins

No clinically important effect on pharmacokinetics of hormonal contraceptives1 200

May be used concomitantly200

Fosamprenavir

Fosamprenavir or ritonavir-boosted fosamprenavir: Decreased concentrations and AUCs of raltegravir and amprenavir (active metabolite of fosamprenavir)205

In vitro evidence of additive to synergistic antiretroviral effects with amprenavir1

Fosamprenavir or ritonavir-boosted fosamprenavir: Appropriate dosages for concomitant use with respect to safety and efficacy not established;205 some experts state dosage adjustments not necessary200

Indinavir

In vitro evidence of additive to synergistic antiretroviral effects1

Lamivudine

No clinically important effect on lamivudine pharmacokinetics1

In vitro evidence of additive to synergistic antiretroviral effects1

Lopinavir/ritonavir

Decreased raltegravir concentrations; no change in lopinavir/ritonavir concentrations200

In vitro evidence of additive to synergistic antiretroviral effects1

Dosage adjustments not needed200

Maraviroc

Decreased raltegravir concentrations and AUC;200 224 decreased maraviroc concentrations and AUC200 224

Not considered clinically important224

Recommended maraviroc dosage is 300 mg twice daily when used with raltegravir, provided regimen does not include a potent CYP3A inhibitor or inducer200 224

Methadone

No clinically important effect on methadone pharmacokinetics1 200

Dosage adjustments not needed200

Nelfinavir

In vitro evidence of additive to synergistic antiretroviral effects1

Nevirapine

In vitro evidence of additive to synergistic antiretroviral effects1

Dosage adjustments not needed200

Proton-pump inhibitors (omeprazole)

Omeprazole: Substantially increased raltegravir concentrations and AUC1 200

Raltegravir not expected to affect pharmacokinetics of proton-pump inhibitors1

Dosage adjustments not needed1 200

Rilpivirine

Data not available;200 clinically important interaction unlikely226

No in vitro evidence of antagonistic antiretroviral effects 226

Ritonavir

Low-dose ritonavir: Decreased raltegravir peak concentrations and AUC1 200

In vitro evidence of additive to synergistic antiretroviral effects1

Dosage adjustments not needed;200 consider possibility of drug interactions between raltegravir and other protease inhibitors (PIs) when low-dose ritonavir is used to boost PI concentrations11

Saquinavir

In vitro evidence of additive to synergistic antiretroviral effects1

Dosage adjustments not needed200

Simeprevir

No clinically important effects on pharmacokinetics of either drug187 200

Dosage adjustments not needed187 200

Sofosbuvir

Decreased raltegravir concentrations and AUC; no clinically important effects on sofosbuvir pharmacokinetics188

Dosage adjustments not needed188

Stavudine

In vitro evidence of additive to synergistic antiretroviral effects1

Tenofovir

Increased raltegravir concentrations and AUC; no clinically important effect on tenofovir DF pharmacokinetics1 200

In vitro evidence of additive to synergistic antiretroviral effects1

Dosage adjustments not needed200

Telaprevir

Increased raltegravir concentrations and AUC; no clinically important effect on telaprevir concentrations or AUC1 184 200

Dosage adjustments not needed1 200

Tipranavir

Ritonavir-boosted tipranavir: Decreased raltegravir concentrations and AUC1 200

Ritonavir-boosted tipranavir: Dosage adjustments not needed1 200

Zidovudine

In vitro evidence of additive to synergistic antiretroviral effects1

Raltegravir Potassium Pharmacokinetics

Absorption

Bioavailability

Absolute bioavailability not established.1

Raltegravir chewable tablets and oral suspension are not bioequivalent to film-coated tablets;1 oral bioavailability is higher with chewable tablets or oral suspension compared with film-coated tablets.1

Film-coated tablets in fasting adults: Peak plasma concentrations attained in approximately 3 hours.1 With twice-daily dosing, steady state achieved within approximately 2 days.1

Chewable tablets in pediatric patients weighing >25 kg: Lower trough plasma concentrations compared with film-coated tablets.1

Food

Studies using film-coated tablets indicate food may increase pharmacokinetic variability, but effect not considered clinically important.1

Chewable tablets: AUC decreased 6% when administered with high-fat meal compared with administration in fasting state.1

Film-coated tablets: Administration with low-fat meal decreased AUC by 46%, administration with moderate-fat meal (600 Kcal, 21 g fat) increased AUC by approximately 13%, and administration with high-fat meal increased AUC by approximately twofold compared with administration in fasting state.1

Oral suspension: Effect of food not studied.1

Distribution

Extent

Distributed into CSF; clinical importance unknown.1

Distributed into milk in rats; not known whether distributed into human milk.1

Crosses human placenta.202

Plasma Protein Binding

83%.1

Elimination

Metabolism

Metabolized mainly by UGT 1A1-mediated glucuronidation in the liver.1 200

Elimination Route

Excreted in feces (51%) and urine (32%).1

Not known if removed by dialysis.1

Half-life

9 hours.1

Special Populations

Moderate hepatic impairment: No clinically important differences in pharmacokinetics compared with healthy individuals.1

Severe hepatic impairment: Pharmacokinetics not studied.1

Severe renal impairment: No clinically important differences in pharmacokinetics compared with healthy individuals.1

Infants, children, and adolescents 4 weeks to 18 years of age receiving recommended pediatric dosage: Pharmacokinetics similar to that reported in adults receiving 400 mg twice daily.1

Common UGT1A1 genotypes associated with reduced UGT1A1 activity do not appear to have clinically important effect on raltegravir pharmacokinetics compared with wild-type UGT1A1 genotype.1

Stability

Storage

Oral

Chewable Tablets

20–25°C (may be exposed to 15–30°C).1

Keep bottle tightly closed; do not remove desiccant.1

Film-coated Tablets

20–25°C (may be exposed to 15–30°C).1

Oral Suspension

20–25°C.1 Do not open single-use foil packet of powder for oral suspension until ready to use.1

After suspending packet contents in water, discard suspension if not used within 30 minutes.1

Actions

  • Inhibits catalytic activity of HIV integrase, an enzyme that integrates HIV DNA into the host cell genome.4 1 Inhibition of integrase prevents propagation of viral infection.1 4

  • Active against HIV type 1 (HIV-1); also has some in vitro activity against HIV type 2 (HIV-2).1 200

  • Raltegravir-resistant HIV-1 have been produced in vitro1 and have emerged during raltegravir therapy.1 17 18

  • Cross-resistance between raltegravir and other INSTIs (e.g., dolutegravir, elvitegravir) reported.19 20 21 22 23 235

Advice to Patients

  • Critical nature of compliance with HIV therapy and importance of remaining under the care of a clinician.1 Importance of taking as prescribed; do not alter or discontinue antiretroviral regimen without consulting clinician.1

  • Importance of using in conjunction with other antiretrovirals—not for monotherapy.1

  • Antiretroviral therapy is not a cure for HIV infection; opportunistic infections and other complications associated with HIV disease may still occur.1 Sustained decreases in plasma HIV RNA have been associated with reduced risk of progression to AIDS and death.1

  • Advise patients that effective antiretroviral regimens can decrease HIV concentrations in blood and genital secretions and strict adherence to such regimens in conjunction with risk-reduction measures may decrease, but cannot absolutely eliminate, the risk of secondary transmission of HIV to others.1 200 Importance of continuing to practice safer sex (e.g., using latex or polyurethane condoms to minimize sexual contact with body fluids), never sharing personal items that can have blood or body fluids on them (e.g., toothbrushes, razor blades), and never reusing or sharing needles.1 200

  • Importance of reading patient information provided by the manufacturer.1

  • If using film-coated tablets, importance of swallowing whole;1 chewable tablets can be chewed or swallowed whole.1

  • If using the oral suspension, importance of parents and/or caregivers reading the manufacturer's instructions for use before preparing and administering the oral suspension.1 Instruct parents and/or caregivers that the oral suspension should be administered within 30 minutes of mixing.1

  • Advise patients not to take aluminum- and/or magnesium-containing antacids concomitantly with or 2 hours before or after raltegravir.1

  • If a dose is missed, the dose should be taken as soon as it is remembered and the next dose taken at the regularly scheduled time.1 If a dose is skipped, a double dose should not be taken to make up for the missed dose.1

  • Importance of informing clinician if unusual symptoms develop or known symptoms persist or worsen.1

  • Advise patients that severe and potentially life-threatening rash has been reported.1 Importance of immediately discontinuing raltegravir and other suspect agents and seeking medical attention if rash occurs and is associated with fever, generally ill feeling, extreme tiredness, muscle or joint aches, breathing difficulty, blisters, oral lesions, eye inflammation, swelling of the face, eyes, lips, or mouth, and/or signs and symptoms of liver problems (e.g., yellowing of skin or whites of the eyes, dark or tea-colored urine, pale stools/bowel movements, nausea, vomiting, loss of appetite, or pain, aching, or sensitivity on the right side below ribs).1

  • Importance of informing clinician if patient has a history of rhabdomyolysis, myopathy, or increased CK concentrations or is receiving drugs known to cause these conditions (e.g., statins, fenofibrate, gemfibrozil, zidovudine).1 Importance of immediately informing clinician if unexplained muscle pain, tenderness, or weakness occurs.1

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal products, and any concomitant illnesses.1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 Advise HIV-infected women not to breast-feed.1

  • Importance of advising patients of other important precautionary information.1 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Raltegravir Potassium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

For suspension

100 mg (of raltegravir) per packet

Isentress

Merck

Tablets, chewable

25 mg (of raltegravir)

Isentress

Merck

100 mg (of raltegravir)

Isentress

Merck

Tablets, film-coated

400 mg (of raltegravir)

Isentress

Merck

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 07/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Isentress 400MG Tablets (MERCK SHARP &amp; DOHME): 60/$1,030.04 or 180/$3,030.04

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions June 30, 2014. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets, chewable tablets, and for oral suspension prescribing information. Whitehouse Station, NJ; 2014 Apr

2. Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010; 50:605-12. [PubMed 20085491]

4. Grinsztejn B, Nguyen BY, Katlama C et al for Protocol 005 team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007; 369:1261-9. [PubMed 17434401]

8. Markowitz M, Nguyen BY, Gotuzzo E et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009; 52:350-6. [PubMed 19648823]

10. Iwamoto M, Kassahun K, Troyer MD et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008; 48:209-14. [PubMed 18077730]

11. Correll T, Klibanov OM. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008: 28:90-101.

12. Merck, North Wales, Pa. Personal communication.

14. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359:339-54. [PubMed 18650512]

15. Nachman S, Zheng N, Acosta EP et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2013; :. [PubMed 24145879]

16. de Kanter CT, Blonk MI, Colbers AP et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013; 56:300-6. [PubMed 23001704]

17. Rockstroh JK, DeJesus E, Lennox JL et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013; 63:77-85. [PubMed 23412015]

18. Eron JJ, Cooper DA, Steigbigel RT et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013; 13:587-96. [PubMed 23664333]

19. Marinello J, Marchand C, Mott BT et al. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry. 2008; 47:9345-54. [PubMed 18702518]

20. Blanco JL, Varghese V, Rhee SY et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011; 203:1204-14. [PubMed 21459813]

21. Garrido C, Villacian J, Zahonero N et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother. 2012; 56:2873-8. [PubMed 22450969]

22. Goethals O, Clayton R, Van Ginderen M et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008; 82:10366-74. [PubMed 18715920]

23. Underwood MR, Johns BA, Sato A et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012; 61:297-301. [PubMed 22878423]

104. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption; aspartame. Final rule. [21 CFR Part 172] Fed Regist. 1983; 48:31376 82.

105. Anon. Aspartame and other sweeteners. Med Lett Drugs Ther. 1982; 24:1 2.

184. Vertex Pharmaceuticals Incorporated. Incivek (telaprevir) film-coated tablets prescribing information. Cambridge, MA; 2012 Jun.

187. Janssen Products LP. Olysio (simeprevir) capsules prescribing information. Titusville, NJ; 2013 Nov.

188. Gilean Sciences Inc. Sovaldi (sofosbuvir) tablet prescribing information. Foster City, CA; 2013 Dec.

199. Kuhar DT, Henderson DK, Struble KA et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013; 34:875-92. [PubMed 23917901]

200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 1, 2014). Updates may be available at HHS AIDS Information (AIDSinfo) website.

201. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in pediatric HIV infection (February 12, 2014). Updates may be available at HHS AIDS Information (AIDSinfo) website.

202. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States (March 28, 2014). Updates may be available at HHS AIDS Information (AIDSinfo) website.

205. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2012 Feb.

214. Janssen. Intelence (etravirine) tablets prescribing information. Raritan, NJ; 2012 Aug.

224. ViiV Healthcare. Selzentry (maraviroc) tablets prescribing information. Research Triangle Park, NC; 2012 Aug.

226. Tibotec Therapeutics. Edurant (rilpivirine) tablets prescribing information. Raritan, NJ; 2012 Aug.

235. Gilead Sciences. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets prescribing information. Foster City, CA; 2013 Oct.

236. GlaxoSmithKline. TIVICAY (dolutegravir) prescribing information. Research Triangle Park, NC; 2013 Aug.

Hide
(web3)